.
.

Continuing Education Activities

Here at JADPRO CE, you can find a valuable array of certified educational opportunities: it’s the place to get your credits and update your learning in oncology. We provide advanced practitioners like you with a wide range of continuing education, covering the most current topics in several formats so you can choose the way you want to learn. You'll find that our CE offerings are easy to navigate. You can sort by topic and/or format, or simply browse the site and get started!

Topic

Format

      Quick Tips →

Multiple Myeloma
Hematologic Malignancies
Side Effect Management
VIDEO

Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)—Optimizing Use of Current Options

Review how to optimize the use of current therapies, including incorporating risk-adapted treatment strategies and keeping up to date with evolving guidelines for evaluating treatment response.

Posted: 7/31/2019 / Expires: 7/31/2020

Estimated time to complete: 30 minutes

Multiple Myeloma
Hematologic Malignancies
Side Effect Management
VIDEO

Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)—Preparing for Novel Agents

Discover the practice-changing implications of novel mechanisms of action, new combinations, and new administration options.

Posted: 7/31/2019 / Expires: 7/31/2020

Estimated time to complete: 30 minutes

Multiple Myeloma
Hematologic Malignancies
Side Effect Management
VIDEO

Enhancing Shared Decision Making in Relapsed/Refractory Multiple Myeloma (RRMM)

Learn how to incorporate patient-centered communication and shared decision making in your practice, thereby improving patient and caregiver adherence, satisfaction, and engagement.

Posted: 7/31/2019 / Expires: 7/31/2020

Estimated time to complete: 30 minutes

Adverse Event Management
VIDEO

Case Study 1: HDMTX-Induced AKI in Osteosarcoma

Using the case of a 31-year-old female patient undergoing treatment for osteosarcoma, Nancy Nix, PharmD, BCPS, BCOP, and Kristi Posey, PA, discuss risk factors for acute kidney injury following high-dose methotrexate (HDMTX) treatment, as well as the importance of pretreatment patient counseling and working as a team to quickly identify and treat delayed HDMTX clearance. They also take a deep dive into the consensus guidelines on the use of glucarpidase rescue and how to correlate clinical findings and lab values to increase the timeliness of treatment decision making.

Posted: 9/10/2019 / Expires: 9/10/2020

Estimated time to complete: 30 minutes

Adverse Event Management
VIDEO

Case Study 2: HDMTX-Induced AKI in CNS Lymphoma

Nancy Nix, PharmD, BCPS, BCOP, and Haleigh Mistry, MS, PA-C, discuss the case of a 58-year-old female patient receiving high-dose methotrexate (HDMTX) as part of treatment for central nervous system lymphoma. Together, they review contraindications to HDMTX; the importance of adequate hydration and urine alkalinization prior to initiating therapy; the mechanisms of action of MTX, glucarpidase, and leucovorin; as well as recent studies demonstrating improved outcomes, decreased mortality, and shorter length of hospital stay among patients receiving glucarpidase for HDMTX-induced acute kidney injury.

Posted: 9/10/2019 / Expires: 9/10/2020

Estimated time to complete: 30 minutes

NSCLC
VIDEO

Disease Overview Followed by Selecting Treatments Using Biomarker Testing and Molecular Profiling

Review of strategies for planning therapy based on results of biomarker tests, liquid biopsies, as well as next-generation sequencing and tumor mutational burden profiles.

Posted: 12/10/2019 / Expires: 12/10/2020

Estimated time to complete: 0.75

NSCLC
VIDEO

Managing Early-Stage and Locally Advanced NSCLC

Discussion of evidence-based management of disease using a multimodal approach that includes surgery, adjuvant chemotherapy, chemoradiation, and immunotherapy.

Posted: 12/10/2019 / Expires: 12/10/2020

Estimated time to complete: 0.75

NSCLC
VIDEO

The Role of Immune Checkpoint Inhibitors With and Without Combination Therapy for Nonmutated Metastatic NSCLC

Analysis of therapeutic approaches using immune checkpoint inhibitors alone or with other agents in first-line setting and beyond.

Posted: 12/10/2019 / Expires: 12/10/2020

Estimated time to complete: 1.0

NSCLC
VIDEO

Managing Immune-Related Adverse Events

Review of clinical and patient education strategies for identifying, mitigating, and addressing adverse events associated with immune checkpoint inhibitors.        

Posted: 12/10/2019 / Expires: 12/10/2020

Estimated time to complete: 0.75

NSCLC
VIDEO

Managing EGFR+ Metastatic NSCLC

Overview of the rationale for targeting EGFR-mutated NSCLC, followed by an evaluation of clinical data and best practices supporting the safe and effective use of EGFR inhibitors in the first-line setting and beyond.

Posted: 12/10/2019 / Expires: 12/10/2020

Estimated time to complete: 0.5

NSCLC
VIDEO

Managing ALK+ and ROS1+ Metastatic NSCLC

Description Overview of the rationale for targeting ALK- and ROS1-mutated NSCLC, followed by an evaluation of clinical data and best practices supporting the safe and effective use of ALK inhibitors in the first-line setting and beyond.

Posted: 12/10/2019 / Expires: 12/10/2020

Estimated time to complete: 0.50

NSCLC
VIDEO

Managing Patients With Other Mutations in Metastatic NSCLC and Upcoming Clinical Trials

Evaluation of the rationale for and clinical data supporting targeting driver mutations in NSCLC, such as BRAF, KRAS, and RET. Appraisal of clinical trials planned or in progress in lung cancer for which preliminary or updated data release has occurred in the past 12 months or is expected in the next 6 months. Discussion of new approvals for small cell lung cancer.

Posted: 12/10/2019 / Expires: 12/10/2020

Estimated time to complete: 0.75

NSCLC
VIDEO

Identifying and Avoiding Drug Interactions

Discussion of best practices for mitigating drug-drug interactions and drug-disease interactions.

Posted: 12/10/2019 / Expires: 12/10/2020

Estimated time to complete: 0.50

NSCLC
VIDEO

Consult the Experts: Case Challenges From Conference Participants

Discussion of clinical decision points involved in challenging patient cases, with a focus on how patient disease characteristics and personal preferences can be used to guide clinical decision-making.

Multiple Myeloma
VIDEO

Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma

Listen as two multiple myeloma experts break down the approved and emerging treatment options for relapsed/refractory multiple myeloma, including mechanisms of action, supporting clinical data, and associated adverse events, ​and discover best practices for selecting and sequencing therapy​.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1.5 hours

VIDEO

Precision Oncology Comes of Age: Tumor-Agnostic Approaches

Guided by two experts in the field, dive into the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (NTRK) fusions. Learn about the clinical trial designs that enable development of these novel therapies, and discover how testing methodologies support the advancement of precision medicine.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: .75 hour

Hematologic Malignancies
VIDEO

New Drug Updates: Hematologic Malignancies

Get updated on the FDA-approved therapies for initial or expanded indications for hematologic malignancies across the past year, as well as their supporting clinical trial data and best practices for safe and effective dosing and administration, drug monitoring, and adverse event management.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 0.75 hours

VIDEO

Addressing the Challenges of Aggressive Lymphomas

Learn how to tackle challenges in the treatment of aggressive lymphomas by understanding how to apply emerging data, reviewing optimal therapies and treatment recommendations, and discovering how to manage associated adverse events in this disease state.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1 hour

Thoracic Cancer
NSCLC
VIDEO

First-Line Therapy for Metastatic Non-Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches

Hone your ability to devise first-line treatment plans for patients with metastatic non–small cell lung cancer, including using biomarkers to guide treatment selection, understanding clinical data supporting use of targeted and immune checkpoint inhibitor therapies, and managing associated adverse events.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1.5 hours

Melanoma
VIDEO

Creating Clarity in Metastatic Melanoma: Optimizing Treatment and Improving Outcomes

Take a deep dive into the diagnosis and treatment landscape for metastatic melanoma, including clinicopathologic features of the disease, approved and emerging therapeutics, and strategies for integrating contemporary standard-of-care management practices. Plus, discover best practices for enhancing collaboration and communication within a multidisciplinary, interprofessional team that fosters shared decision-making.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1.5 hours

Breast Cancer
VIDEO

Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments

Learn from two experts in the field of breast cancer as they discuss the current and future treatment landscape for triple-negative breast cancer, including recent and emerging data on approved treatments, novel therapeutic options being investigated, and best practices for identifying and monitoring adverse events associated with PARP and immune checkpoint inhibitors.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1.5 hours

Novel Therapy
VIDEO

Biomarker BINGO

Test your knowledge on biomarkers and their use in determining targeted therapy for certain tumor types, key assays used to measure common biomarkers, and guideline-endorsed biomarker testing recommendations.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1 hour

PARP
Ovarian Cancer
VIDEO

Current and Future Directions in PARP Inhibition

Review how far PARP inhibition has come and discover where it’s headed, including its potential role in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that include PARP inhibitors for patients with ovarian or breast cancer based on genetic profiles, tolerability, dosing schedules, and other factors.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1 hour

VIDEO

Recent Advances in the Treatment of Newly Diagnosed Multiple Myeloma

Watch as two experts in the field of multiple myeloma (MM) interpret data on current and novel treatments, discuss how to select initial therapy based on patient risk and in alignment with guidelines and best practices, and evaluate the use of minimal residual disease testing in patients with MM.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1 hour

Checkpoint Inhibition
VIDEO

Immune Checkpoint Inhibitor-Based Therapy as a Backbone in Cancer Treatment

Review the basic concepts of immunotherapy and the current treatment landscape; explore important aspects of IO care, including the microbiome, provider-patient communication, and survivorship; and evaluate emerging data for ICI-based combinations that are being explored in late-stage clinical trials.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1 hour

CAR T-Cell Therapy
VIDEO

Adoptive Cell Therapies: Keeping Pace With New and Emerging Advances

Discover the emerging world of chimeric antigen receptor (CAR) T-cell therapy, including the CAR T-cell process, approved indications and studies in hematologic malignancies, strategies for monitoring and managing emerging toxicities, and future directions in the use of this novel therapy.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1 hour

CLL
VIDEO

Improving Outcomes for Patients With Chronic Lymphocytic Leukemia

Review data regarding mechanistic activity, efficacy, and safety of approved and emerging therapeutic options for chronic lymphocytic leukemia (CLL), discover how to devise risk-stratified treatment plans, and learn strategies for managing adverse events associated with approved therapies for CLL.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1.5 hours

Urothelial Carcinoma
VIDEO

Improving Outcomes for Patients With Advanced Urothelial Carcinoma of the Bladder

Discover how to select appropriate lines of therapy for treatment of advanced or metastatic urothelial carcinoma and manage associated adverse events in accordance with evidence-based best practices, and learn what’s on the horizon in the treatment of this disease state.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1.5 hours

HER2 Positive Breast Cancer
Breast Cancer
VIDEO

Improving Outcomes in HER2+ Breast Cancer: Analysis and Application of Evolving Data and Best Practices

Through expert, case-based discussion, learn about existing and emerging data for current and investigational therapies for HER2+ breast cancer and their associated adverse events, in addition to best practices for managing central nervous system metastases.

Posted: 2/15/2020 / Expires: 2/14/2021

Estimated time to complete: 1.5 hours

Immunotherapy
Print

Immuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events

This supplement to JADPRO has been developed in partnership with the AIM With Immunotherapy Immuno-Oncology Essentials group and Terranova Medica. The Appendix includes 12 Care Step Pathways (CSPs), step-by-step guides that are designed to provide comprehensive assessment and management strategies for toxicities unique to immunotherapies. These CSPs work across tumor types, and each of them is discussed in detail in the supplement articles.

Posted: 3/21/2019 / Expires: 3/21/2020

Estimated time to complete: 3 hours

Breast
Print

Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management

The article discusses existing and emerging data in HER2+ breast cancer, effectively managing diarrhea and other adverse events associated with treatments, and implementing best practices for the management of HER2+ breast cancer brain metastases.

Posted: 3/21/2019 / Expires: 3/21/2020

Estimated time to complete: 0.5 hour

Checkpoint Inhibition
Immunotherapy
irAEs
Side Effect Management
Print
Video

Narratives on Collaboration: Optimizing Management of Immune-Related Adverse Events

Learn about best practices for managing irAEs from this interactive JADPRO article, which includes videos, polling, downloadable patient tools and resources, and more.

Posted: July 12, 2019 / Expires: July 12, 2020

Estimated time to complete: 1.0 hour

CAR T-Cell Therapy
Adverse Event Management
Print

The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Cytokine Release Syndrome From CAR T-Cell Therapy

Despite remarkable promise, CAR T-cell therapies are associated with varied adverse effects, including cytokine release syndrome (CRS), neurotoxicity, and cytopenias. The incidence of CRS has been reported to be as high as 94%. It is imperative that advanced practitioners have the necessary know-how to effectively prevent, treat, and manage CRS related to CAR T-cell therapy.

Posted: November 21, 2019 / Expires: November 21, 2020

Estimated time to complete: 1.0 hour

AML
Hematologic Malignancies
Print

Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners

Created by AML experts Nancy Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-C, these articles will help you navigate this complex disease, including next-generation sequencing, risk stratification, and use of recently approved therapies, all within the context of interpreting the continually evolving guidelines. The comprehensive Appendix section also lists all of the key information about FDA-approved therapies for AML at a glance.

Posted: December 20, 2019 / Expires: December 19, 2020

Estimated time to complete: 1.0 hour

Myelofibrosis
Video
Print

Responding to the Evolving Treatment Paradigm for Myelofibrosis: Narratives in Collaboration

Access a full-length article, videos, a Q&A session, and resources on the role of the advanced practitioner in treating patients with myelofibrosis.

Posted: December 20, 2019 / Expires: December 19, 2020

Estimated time to complete: 1.0 hour

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.